Anteris Reports Positive Biomimetic Heart Valve Study Results
Anteris Technologies (Nasdaq:AVR) announced one-year clinical outcomes for i…
Regeneron's Eylea HD Rejected by FDA
Regeneron is planning to re-apply to the FDA with a new pre-filled syringe manufacturing filler in Ja…
European Parliament Considers Banning Russian Media
The European Parliament is weighing whether to ban access to Russian websites, such as…
Landmark Report Exposes Conflict of Interest in Canadian Lobbying
A recent study by FMinus reveals that Canadian lobbyists represent both …
Market Watch: Regeneron, UPS, and Zebra
Regeneron (REGN) has seemingly overcome its bear phase, with shares rebounding from $550-$575 to o…
Eddie Glaude Jr. on Challenging MAGA
Eddie Glaude Jr. suggests a simple response to false claims made by Trump supporters: "You're lying."…
Preventing Infections after Surgery for Lower Limb Arteries
Peripheral artery disease (PAD) is a condition where the arteries that supply …